Immune cell vaccine plus checkpoint treatment after liver radiation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your liver cancer must be one of these types: intrahepatic cholangiocarcinoma, or hepatocellular carcinoma (but not one that can be removed with surgery).
- Your scans must show no cancer outside the liver (except a blood-vessel tumor clot), and your cancer must have spots that radiation can treat safely.
- A doctor must be able to reach the tumor with an ultrasound-guided injection to place the immune cells directly into the tumor.
- Your overall health needs to be good enough for study treatment (ECOG 0–1) and your blood counts/liver/kidney tests must meet specific thresholds (the trial lists required minimums).
- You must be able to sign consent, return for follow-up at the study center, and provide required blood and tissue samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) plus targeted proton radiation for liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink tumors and improve outcomes for people with intermediate or advanced stage liver cancer.
Hear when a new Stage III Hepatocellular Carcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.